PARP1 and cervical carcinoma: We recently demonstrated that in cervical cancer cells (HPV-positive CaSki and C-4I), a perturbation in the balanced expression/activation of STAT1 and STAT3 might improve the efficacy of DNA-damaging treatments, at least partially, by lowering PARP1 levels in tumors [17].